Journals / Fırat Tıp Dergisi / 2009 / Cilt: 14 - Sayı: 3

Benign prostat hiperplazili hastalarda doksazosinin prostatik rezistif indeks üzerine etkisi

Effect of doxazosin on prostatic resistive index in patients with benign prostate hyperplasia

Pages
171–174
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that prostatic RI could be a useful parameter for the follow-up of patients receiving medical treatment with BPH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In recent years several studies revealed that prostatic resistive index (RI) was increased on power Doppler imaging (PDI) in patients with benign prostate hyperplasia (BPH).
📊
Key Findings & Data:All patients received 8mg Doxazosin daily for six months.
💡
Conclusion & Impact:We believe that prostatic RI could be a useful parameter for the follow-up of patients receiving medical treatment with BPH.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In recent years several studies revealed that prostatic resistive index (RI) was increased on power Doppler imaging (PDI) in patients with benign prostate hyperplasia (BPH). In the present study we aimed to evaluate the effect of Doxazosin on prostatic RI in BPH patients. Materials and Methods: Forty BPH patients with lower urinary tract symptoms included in this study. All patients received 8mg Doxazosin daily for six months. International prostatic symptom scores (IPSS), maximal urine flow rates (Qmax), total prostate volumes and prostatic RI determination with PDI were compared before and after the treatment. Results: The mean age, IPSS and Qmax of the patients was 60.2±2 years, 20.3±4.5 and 11.3±3.0 mL/s respectively. There was a positive correlation between prostatic RI, total prostate volume and IPSS before the treatment (r=0.37 p=0.02 and r=0.40 p=0.017, respectively). On the other hand there was a negative correlation between prostatic RI and Qmax values (r= -0.38 p=0.021). There was a significant improvement in IPSS scores and Qmax values after the treatment (7.9±5.3 and 16.8±5.8 mL/s respectively, p<0.05). It was demonstrated that prostatic RI of the patients significantly decreased when compared to pretreatment levels (0.74±0.06 and 0.69±0.05 respectively, p<0.05). Conclusion: Our data demonstrated that Doxazosin treatment significantly decreased prostatic RI of the patients with BPH. We believe that prostatic RI could be a useful parameter for the follow-up of patients receiving medical treatment with BPH.

Özet

Amaç: Son yıllarda yapılan birkaç çalışmada benign prostat hiperplazili (BPH) hastaların power doppler ultrasonografi (USG) ile tespit edilen prostatik rezistif indekslerinde artış tespit edilmiştir. Bu çalışmada BPH’lı hastalarda doksazosin tedavisinin prostatik rezistif indeks üzerine etkisi değerlendirildi. Gereç ve Yöntemler: Çalışmaya alt üriner sistem semptomları nedeniyle BPH düşünülen 40 hasta alındı. Tüm hastalara 6 ay boyunca günde 8 mg doksazosin tedavisi verildi. Tedavi öncesi ve sonrası hastaların uluslararası semptom skorları (IPSS), maksimal akım hızları (Qmax), total prostat volümleri (TPV) ve power doppler USG ile tespit edilen prostatik rezistif indeksleri karşılaştırıldı. Bulgular: Hastaların ortalama yaşı 60.2±2 yıl, IPSS 20.3±4.5 ve Qmax 11.3 ±3.0 m/sn idi. Tedavi öncesi hastaların prostatik rezistive indeksi ile TPV ve IPSS arasında pozitif (sırasıyla, r=0.37 p=0.02 ve r=0.40 p=0.017), Qmax arasında negatif korelasyon tespit edildi (r=-0.38 p=0.021).Tedavi sonrası hastaların IPSS ve Qmax değerlerinde anlamlı derecede iyileşme mevcuttu (sırasıyla,7.9±5.3 ve 16.8±5.8, p<0.05). Tedavi öncesine göre hastaların prostatik rezistif indekslerinin anlamlı derecede azaldığı tespit edildi (sırasıyla,0.74±0.06 ve 0.69±0.05, p<0.05). Sonuç: Elde ettiğimiz veriler BPH’lı hastalarda doksazosin tedavisinin prostatik rezistif indeksi anlamlı derecede azatlığını göstermiştir. Bu nedenle medikal tedavi verilen BPH’lı hastaların takibinde prostatik resiztif indeks faydalı bir parametre olabilir.

🔖

Cite This Article

ÖZDEN, C., GÜNAY, İ., DEREN, T., BULUT, S., KOPARAL, S., MEMİŞ, A. (2009). Benign prostat hiperplazili hastalarda doksazosinin prostatik rezistif indeks üzerine etkisi. Fırat Tıp Dergisi, Cilt: 14 - Sayı: 3, 171–174. https://ajindex.com/articles/223737

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479
  2. Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology 1995; 46 (supp l):23-25
  3. Kumar VL, Dewan S. Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate. Int Urol Nephrol 2000; 32: 67-71
  4. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 2003; 62 (Suppl 1):24-33
  5. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008;15:193-199
  6. Pool JL, Kirby RS. Clinical significance of alpha1- adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int Urol Nephrol 2001; 33: 407-412
  7. Scarpa RM. Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 2001; 40 (Suppl 4):12-20
  8. Porru D, Madeddu G, Campus G, Montisci I, Scarpa RM, Usai E. Evaluation of morbidity of multi-channel pressure-flow studies. Neurourol Urodyn. 1999; 18(6):647-652
  9. Kortmann BB, Sonke GS, D'ancona FC, Floratos DL, Debruyne FM, De La Rosette JJ. The tolerability of urodynamic studies and flexible cysto-urethroscopy used in the assessment of men with lower urinary tract symptoms. BJU Int 1999; 84: 449-453
  10. Tsuru N, Kurita Y, Suzuki K, Fujita K. Resistance index in benign prostatic hyperplasia using power Doppler imaging and clinical outcomes after transurethral vaporization of the prostate. Int J Urol 2005;12: 264-269
  11. Hayami S, Ushiyama T, Kurita Y, Kageyama S, Suzuki K, Fujita K. The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia. Prostate 2002; 53: 168-174
  12. Tsuru N, Kurita Y, Masuda H, Suzuki K, Fujita K. Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol 2002; 9: 427-430
  13. Kojima M, Watanabe H, Watanabe M, Okihara K, Naya Y, Ukimura O. Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Biol 1997; 23: 1305-1309
  14. Ozdemir H, Onur R, Bozgeyik Z, Orhan I, Ogras MS, Ogur E. Measuring resistance index in patients with BPH and lower urinary tract symptoms. J Clin Ultrasound 2005; 33:176-180
  15. Kojima M, Ochiai A, Naya Y, Okihara K, Ukimura O, Miki T. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infrav